Taros Chemicals and Welab Barcelona partner for drug Discovery and development services
The combination will support clients in getting their end-to-end discovery and development programs delivered.
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
Brimonidine Tartrate Ophthalmic Solution is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Subscribe To Our Newsletter & Stay Updated